Insulin-like growth factor 1 receptor inhibitors: Where do we come from? What are we? Where are we going?

Authors

  • Bartosz Chmielowski MD, PhD

    Corresponding author
    1. Division of Hematology-Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California
    • Corresponding author: Bartosz Chmielowski, MD, PhD, Division of Hematology-Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, 2825 Santa Monica Boulevard, Suite 200, Santa Monica, CA 90404; Fax: (310) 443-0477; bchmielowski@mednet.ucla.edu

    Search for more papers by this author

  • See related original on pages 2448–56, this issue.

Abstract

The author comments on results from the phase 2 trial of R1507 in patients with sarcoma in the landscape of the disappointing results from clinical trials with insulin-like growth factor 1 receptor inhibitors.

Ancillary